Fitzgerald Joseph Kevin's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 7,763 Common Stock done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 7,763 | 21,264 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 7,819 | 7,819 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 3,871 | 16,256 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 243.94 per share. | 03 Mar 2025 | 487 | 14,564 (0%) | 0% | 243.9 | 118,799 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 242.69 per share. | 03 Mar 2025 | 465 | 15,051 (0%) | 0% | 242.7 | 112,851 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 240.95 per share. | 03 Mar 2025 | 328 | 13,896 (0%) | 0% | 241.0 | 79,032 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 241.68 per share. | 03 Mar 2025 | 324 | 13,572 (0%) | 0% | 241.7 | 78,304 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 243.36 per share. | 03 Mar 2025 | 224 | 15,828 (0%) | 0% | 243.4 | 54,513 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 245.30 per share. | 03 Mar 2025 | 219 | 14,345 (0%) | 0% | 245.3 | 53,721 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 242.37 per share. | 03 Mar 2025 | 204 | 16,052 (0%) | 0% | 242.4 | 49,443 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 244.41 per share. | 03 Mar 2025 | 151 | 15,677 (0%) | 0% | 244.4 | 36,906 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 239.24 per share. | 03 Mar 2025 | 121 | 14,224 (0%) | 0% | 239.2 | 28,948 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 245.26 per share. | 03 Mar 2025 | 111 | 15,566 (0%) | 0% | 245.3 | 27,224 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 242.93 per share. | 03 Mar 2025 | 71 | 13,501 (0%) | 0% | 242.9 | 17,248 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 246.18 per share. | 03 Mar 2025 | 45 | 15,521 (0%) | 0% | 246.2 | 11,078 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 247.25 per share. | 03 Mar 2025 | 4 | 15,517 (0%) | 0% | 247.3 | 989 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 248.00 per share. | 03 Mar 2025 | 1 | 15,516 (0%) | 0% | 248 | 248 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 242.44 per share. | 28 Feb 2025 | 187 | 12,497 (0%) | 0% | 242.4 | 45,336 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 241.51 per share. | 28 Feb 2025 | 79 | 12,684 (0%) | 0% | 241.5 | 19,079 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 243.23 per share. | 28 Feb 2025 | 75 | 12,422 (0%) | 0% | 243.2 | 18,242 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 240.31 per share. | 28 Feb 2025 | 48 | 12,763 (0%) | 0% | 240.3 | 11,535 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 244.11 per share. | 28 Feb 2025 | 37 | 12,385 (0%) | 0% | 244.1 | 9,032 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 236.52 per share. | 28 Feb 2025 | 27 | 12,854 (0%) | 0% | 236.5 | 6,386 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 239.18 per share. | 28 Feb 2025 | 22 | 12,811 (0%) | 0% | 239.2 | 5,262 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 238.33 per share. | 28 Feb 2025 | 21 | 12,833 (0%) | 0% | 238.3 | 5,005 | Common Stock |
| Ovid Therapeutics Inc | Kevin Joseph Fitzgerald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 2,103 | 14,984 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 250.21 per share. | 13 Feb 2025 | 1,086 | 13,235 (0%) | 0% | 250.2 | 271,728 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 253.37 per share. | 13 Feb 2025 | 164 | 14,675 (0%) | 0% | 253.4 | 41,553 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 252.50 per share. | 13 Feb 2025 | 145 | 14,839 (0%) | 0% | 252.5 | 36,613 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 251.60 per share. | 13 Feb 2025 | 115 | 13,120 (0%) | 0% | 251.6 | 28,934 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 254.35 per share. | 13 Feb 2025 | 110 | 14,565 (0%) | 0% | 254.4 | 27,979 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 259.10 per share. | 13 Feb 2025 | 83 | 12,881 (0%) | 0% | 259.1 | 21,505 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 256.05 per share. | 13 Feb 2025 | 80 | 13,040 (0%) | 0% | 256.1 | 20,484 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 257.79 per share. | 13 Feb 2025 | 76 | 12,964 (0%) | 0% | 257.8 | 19,592 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 256.28 per share. | 13 Feb 2025 | 53 | 14,465 (0%) | 0% | 256.3 | 13,583 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 255.55 per share. | 13 Feb 2025 | 47 | 14,518 (0%) | 0% | 255.6 | 12,011 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 258.06 per share. | 13 Feb 2025 | 33 | 14,406 (0%) | 0% | 258.1 | 8,516 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 257.50 per share. | 13 Feb 2025 | 26 | 14,439 (0%) | 0% | 257.5 | 6,695 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 261.46 per share. | 13 Feb 2025 | 26 | 14,347 (0%) | 0% | 261.5 | 6,798 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 260.57 per share. | 13 Feb 2025 | 21 | 14,373 (0%) | 0% | 260.6 | 5,472 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 264.86 per share. | 13 Feb 2025 | 14 | 14,321 (0%) | 0% | 264.9 | 3,708 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 259.75 per share. | 13 Feb 2025 | 12 | 14,394 (0%) | 0% | 259.8 | 3,117 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 263.33 per share. | 13 Feb 2025 | 12 | 14,335 (0%) | 0% | 263.3 | 3,160 | Common Stock |
| Ovid Therapeutics Inc | Kevin Joseph Fitzgerald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Alnylam Pharmaceuticals Inc | Joseph Fitzgerald Kevin | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Nov 2024 | 3,000 | 15,881 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Kevin Fitzgerald Joseph | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 251.98 per share. | 25 Nov 2024 | 851 | 13,351 (0%) | 0% | 252.0 | 214,435 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Fitzgerald Joseph | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 251.42 per share. | 25 Nov 2024 | 826 | 14,496 (0%) | 0% | 251.4 | 207,673 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 253.44 per share. | 25 Nov 2024 | 360 | 12,991 (0%) | 0% | 253.4 | 91,238 | Common Stock |
| Alnylam Pharmaceuticals Inc | Fitzgerald Joseph Kevin | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 250.68 per share. | 25 Nov 2024 | 318 | 15,322 (0%) | 0% | 250.7 | 79,716 | Common Stock |
| Alnylam Pharmaceuticals Inc | Joseph Fitzgerald Kevin | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 249.60 per share. | 25 Nov 2024 | 215 | 15,640 (0%) | 0% | 249.6 | 53,664 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Fitzgerald Joseph | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 250.45 per share. | 25 Nov 2024 | 210 | 14,202 (0%) | 0% | 250.5 | 52,595 | Common Stock |
| Alnylam Pharmaceuticals Inc | Fitzgerald Joseph Kevin | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 254.48 per share. | 25 Nov 2024 | 110 | 12,881 (0%) | 0% | 254.5 | 27,993 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 252.27 per share. | 25 Nov 2024 | 84 | 14,412 (0%) | 0% | 252.3 | 21,191 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Fitzgerald Joseph | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 247.77 per share. | 25 Nov 2024 | 26 | 15,855 (0%) | 0% | 247.8 | 6,442 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 14,058 | 2,192 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 85.00 per share. | 12 Aug 2024 | 14,058 | 34,906 (0%) | 0% | 85 | 1,194,930 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 270.17 per share. | 12 Aug 2024 | 9,662 | 23,823 (0%) | 0% | 270.2 | 2,610,383 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 97.72 per share. | 12 Aug 2024 | 6,667 | 20,848 (0%) | 0% | 97.7 | 651,499 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 6,667 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 271.32 per share. | 12 Aug 2024 | 5,736 | 18,087 (0%) | 0% | 271.3 | 1,556,292 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 272.43 per share. | 12 Aug 2024 | 3,913 | 14,174 (0%) | 0% | 272.4 | 1,066,019 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 268.66 per share. | 12 Aug 2024 | 1,421 | 33,485 (0%) | 0% | 268.7 | 381,766 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 273.73 per share. | 12 Aug 2024 | 1,158 | 13,016 (0%) | 0% | 273.7 | 316,979 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 274.65 per share. | 12 Aug 2024 | 135 | 12,881 (0%) | 0% | 274.7 | 37,078 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 2,498 | 15,379 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 229.93 per share. | 24 Jun 2024 | 227 | 14,765 (0%) | 0% | 229.9 | 52,194 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 229.06 per share. | 24 Jun 2024 | 198 | 14,992 (0%) | 0% | 229.1 | 45,354 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 232.54 per share. | 24 Jun 2024 | 161 | 14,530 (0%) | 0% | 232.5 | 37,439 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 234.66 per share. | 24 Jun 2024 | 138 | 14,306 (0%) | 0% | 234.7 | 32,383 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 235.19 per share. | 24 Jun 2024 | 125 | 14,181 (0%) | 0% | 235.2 | 29,399 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 228.30 per share. | 24 Jun 2024 | 96 | 15,190 (0%) | 0% | 228.3 | 21,917 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 233.53 per share. | 24 Jun 2024 | 86 | 14,444 (0%) | 0% | 233.5 | 20,084 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 231.59 per share. | 24 Jun 2024 | 74 | 14,691 (0%) | 0% | 231.6 | 17,138 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 221.71 per share. | 24 Jun 2024 | 45 | 15,334 (0%) | 0% | 221.7 | 9,977 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 226.81 per share. | 24 Jun 2024 | 26 | 15,286 (0%) | 0% | 226.8 | 5,897 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 225.54 per share. | 24 Jun 2024 | 13 | 15,312 (0%) | 0% | 225.5 | 2,932 | Common Stock |
| Alnylam Pharmaceuticals Inc | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sale of securities on an exchange or to another person at price $ 224.22 per share. | 24 Jun 2024 | 9 | 15,325 (0%) | 0% | 224.2 | 2,018 | Common Stock |
| Ovid Therapeutics Inc | Fitzgerald Joseph Kevin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Ovid Therapeutics Inc | Kevin Joseph Fitzgerald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Ovid Therapeutics Inc | Kevin Joseph Fitzgerald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) |